Form 13-F position report

ARROWHEAD PHARMACEUTICALS INC

Reported by M28 Capital Management LP

ARWR CUSIP 04280A100 Manager CIK 0001807489

Reported 67,400 shares, unchanged from the prior quarter.

Reported value 13.9%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.71% This manager · Q4 2023
Shares 67,400 Quarter-end amount reported
Reported value $2,062,440 Fair value at quarter end
Consecutive quarters held 5 Through Q4 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 5836584
2023-03-31 1711960
2023-06-30 2403484
2023-09-30 1811038
2023-12-31 2062440
2024-03-31 1927640
2024-06-30 1751726
2024-09-30 1305538
2024-12-31 1267120
2025-03-31 858676
2025-06-30 1064920
2025-09-30 2324626
2025-12-31 4474686
2026-03-31 2310558
2026-06-30 3003725

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for ARROWHEAD PHARMACEUTICALS INC held by M28 Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Unchanged 36,851 0 (0.0%) 6.37% $3,003,725 2026-08-13
Q1 2026 Reduced 36,851 -30,549 (-45.3%) 4.29% $2,310,558 2026-05-14
Q4 2025 Unchanged 67,400 0 (0.0%) 3.25% $4,474,686 2026-02-13
Q3 2025 Unchanged 67,400 0 (0.0%) 3.42% $2,324,626 2025-11-13
Q2 2025 Unchanged 67,400 0 (0.0%) 1.82% $1,064,920 2025-08-13
Q1 2025 Unchanged 67,400 0 (0.0%) 1.18% $858,676 2025-05-14
Q4 2024 Unchanged 67,400 0 (0.0%) 1.24% $1,267,120 2025-02-13
Q3 2024 Unchanged 67,400 0 (0.0%) 1.43% $1,305,538 2024-11-12
Q2 2024 Unchanged 67,400 0 (0.0%) 2.27% $1,751,726 2024-08-13
Q1 2024 Unchanged 67,400 0 (0.0%) 1.42% $1,927,640 2024-05-14
Q4 2023 Unchanged 67,400 0 (0.0%) 1.71% $2,062,440 2024-02-12
Q3 2023 Unchanged 67,400 0 (0.0%) 2.08% $1,811,038 2023-11-13
Q2 2023 Unchanged 67,400 0 (0.0%) 3.18% $2,403,484 2023-08-11
Q1 2023 Reduced 67,400 -76,500 (-53.2%) 1.94% $1,711,960 2023-05-12
Q4 2022 New 143,900 +143,900 (0.0%) 5.56% $5,836,584 2023-02-10

Who else reported the position

301 managers reported ARROWHEAD PHARMACEUTICALS INC for Q4 2023.

Managers reporting ARROWHEAD PHARMACEUTICALS INC in Q4 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 13,303,757 +464,263 0.01% $407,094,965 31 qtrs
VANGUARD GROUP INC Reduced 10,672,076 -186,239 < 0.01% $326,565,525 31 qtrs
STATE STREET CORPORATION Added 6,825,111 +962,146 0.01% $208,848,397 32 qtrs
FMR LLC Reduced 3,371,268 -937,635 < 0.01% $103,160,815 22 qtrs
JPMorgan Chase & Co Reduced 2,751,048 -32,050 < 0.01% $84,182,068 31 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,326,876 +108,623 < 0.01% $71,210,442 31 qtrs
Invesco Ltd Reduced 2,306,308 -136,730 0.02% $70,573,024 23 qtrs
CREDIT SUISSE AG Added 1,745,342 +216,664 0.05% $53,407,466 25 qtrs
Slate Path Capital LP New 1,329,000 +1,329,000 0.9% $40,667,400 1 qtr
NORGES BANK Added 1,321,927 +175,602 < 0.01% $40,450,966 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2023
Filed
February 12, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
67,400
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.